{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T14:26:38Z","timestamp":1777127198406,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40120-022-00370-8","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T16:04:32Z","timestamp":1655309072000},"page":"1235-1252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"370_CR1","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163\u201396.","journal-title":"Lancet"},{"key":"370_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629\u2013808.","journal-title":"Cephalalgia"},{"key":"370_CR3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84:422\u201335.","journal-title":"Mayo Clin Proc"},{"key":"370_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jval.2012.08.2212","volume":"16","author":"D Serrano","year":"2013","unstructured":"Serrano D, Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Value Health. 2013;16:31\u20138.","journal-title":"Value Health"},{"key":"370_CR5","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/j.1526-4610.2011.01945.x","volume":"51","author":"M Stokes","year":"2011","unstructured":"Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51:1058\u201377.","journal-title":"Headache"},{"key":"370_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361\u201378.","journal-title":"J Headache Pain"},{"key":"370_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54\u201361.","journal-title":"Cephalalgia"},{"key":"370_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10194-008-0036-8","volume":"9","author":"LH Lassen","year":"2008","unstructured":"Lassen LH, Jacobsen VB, Haderslev PA, et al. Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain. 2008;9:151\u20137.","journal-title":"J Headache Pain"},{"key":"370_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0304-3959(00)00232-3","volume":"86","author":"M Ashina","year":"2000","unstructured":"Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000;86:133\u20138.","journal-title":"Pain"},{"key":"370_CR10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Morollon","year":"2013","unstructured":"Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191\u20136.","journal-title":"Neurology"},{"key":"370_CR11","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/j.1526-4610.2009.01523.x","volume":"49","author":"RK Cady","year":"2009","unstructured":"Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49:1258\u201366.","journal-title":"Headache"},{"key":"370_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/head.12250","volume":"54","author":"R Cady","year":"2014","unstructured":"Cady R, Turner I, Dexter K, Beach ME, Cady R, Durham P. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine. Headache. 2014;54:269\u201377.","journal-title":"Headache"},{"key":"370_CR13","unstructured":"Qulipta-FDA. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf. Accessed Dec 2021."},{"key":"370_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"370_CR15","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Higgins JPT and Green S, editors. The Cochrane Collaboration, 2011. http:\/\/handbook-5-1.cochrane.org\/. Accessed Dec 2021."},{"key":"370_CR16","unstructured":"GRADE Handbook-Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach [updated October 2013]. Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html. Accessed Jan 2022."},{"key":"370_CR17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"370_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Zaccara G, et al. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020;34:1105\u201320.","journal-title":"CNS Drugs"},{"key":"370_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40263-020-00708-6","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Brigo F, Trinka E, et al. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34:229\u201341.","journal-title":"CNS Drugs"},{"key":"370_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/epi.16546","volume":"61","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61:1090\u20138.","journal-title":"Epilepsia"},{"key":"370_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000488401","volume":"45","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Cagnetti C, Di Napoli M, Silvestrini M. Patent foramen ovale and cryptogenic stroke or transient ischemic attack: to close or not to close? A systematic review and meta-analysis. Cerebrovasc Dis. 2018;45:193\u2013203.","journal-title":"Cerebrovasc Dis"},{"key":"370_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00415-017-8681-y","volume":"265","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Grillo E, Brigo F, Silvestrini M. Efficacy and safety of perampanel in Parkinson\u2019s disease. A systematic review with meta-analysis. J Neurol. 2018;265:733\u201340.","journal-title":"J Neurol"},{"key":"370_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol. 2020;19:727\u201337.","journal-title":"Lancet Neurol"},{"key":"370_CR24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695\u2013706.","journal-title":"N Engl J Med"},{"key":"370_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","volume":"42","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, Lipton RB, Ailani J, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022;42:3\u201311.","journal-title":"Cephalalgia"},{"key":"370_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","volume":"19","author":"T Schwedt","year":"2018","unstructured":"Schwedt T, Reuter U, Tepper S, et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018;19:92.","journal-title":"J Headache Pain"},{"key":"370_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15197","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N, et al. Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicentre, Italian real-life study. Eur J Neurol. 2021. https:\/\/doi.org\/10.1111\/ene.15197.","journal-title":"Eur J Neurol"},{"key":"370_CR28","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/head.13654","volume":"59","author":"PK Winner","year":"2019","unstructured":"Winner PK, Spierings ELH, Yeung PP, et al. Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache. 2019;59:1743\u201352.","journal-title":"Headache"},{"key":"370_CR29","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Gottschalk C, Cady R, et al. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache. 2020;60:2220\u201331.","journal-title":"Headache"},{"key":"370_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","volume":"79","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Brigo F, Trinka E, et al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019;79:417\u201331.","journal-title":"Drugs"},{"key":"370_CR31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneur.61.4.490","volume":"61","author":"SD Silberstein","year":"2004","unstructured":"Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490\u20135.","journal-title":"Arch Neurol"},{"key":"370_CR32","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jama.291.8.965","volume":"291","author":"JL Brandes","year":"2004","unstructured":"Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965\u201373.","journal-title":"JAMA"},{"key":"370_CR33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/14740338.2015.1014797","volume":"14","author":"L V\u00e9csei","year":"2015","unstructured":"V\u00e9csei L, Majl\u00e1th Z, Szok D, Cs\u00e1ti A, Tajti J. Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf. 2015;14:667\u201381.","journal-title":"Expert Opin Drug Saf"},{"key":"370_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1476-5381.2011.01633.x","volume":"166","author":"EL Moore","year":"2012","unstructured":"Moore EL, Salvatore CA. Targeting a family B GPCR\/RAMP receptor complex: CGRP receptor antagonists and migraine. Br J Pharmacol. 2012;166:66\u201378.","journal-title":"Br J Pharmacol"},{"key":"370_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s42466-020-00057-1","volume":"2","author":"HC Diener","year":"2020","unstructured":"Diener HC, F\u00f6rderreuther S, Gaul C, et al. Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: addition to the S1 guideline: therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society. Neurol Res Pract. 2020;2:11.","journal-title":"Neurol Res Pract"},{"key":"370_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ana.410200409","volume":"20","author":"I Jansen","year":"1986","unstructured":"Jansen I, Uddman R, Hocherman M, et al. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Ann Neurol. 1986;20:496\u2013501.","journal-title":"Ann Neurol"},{"key":"370_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0306-4522(88)90018-8","volume":"25","author":"PK Mulderry","year":"1988","unstructured":"Mulderry PK, Ghatei MA, Spokes RA, et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988;25:195\u2013205.","journal-title":"Neuroscience"},{"key":"370_CR38","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/head.13795","volume":"60","author":"K Falkenberg","year":"2020","unstructured":"Falkenberg K, Bjerg HR, Olesen J. Two-hour CGRP infusion causes gastrointestinal hyperactivity: possible relevance for CGRP antibody treatment. Headache. 2020;60:929\u201337.","journal-title":"Headache"},{"key":"370_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;61:363\u201372.","journal-title":"Headache"},{"key":"370_CR40","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache. 2021;61:1351\u201363.","journal-title":"Headache"},{"key":"370_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bph.14075","volume":"175","author":"DL Hay","year":"2018","unstructured":"Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR review 25. Br J Pharmacol. 2018;175:3\u201317.","journal-title":"Br J Pharmacol"},{"key":"370_CR42","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","volume":"28","author":"A Negro","year":"2019","unstructured":"Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28:555\u201367.","journal-title":"Expert Opin Investig Drugs"},{"key":"370_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/cts.12917","volume":"14","author":"KC Min","year":"2021","unstructured":"Min KC, Kraft WK, Bondiskey P, et al. Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults. Clin Transl Sci. 2021;14:599\u2013605.","journal-title":"Clin Transl Sci"},{"key":"370_CR44","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099\u2013142.","journal-title":"Physiol Rev"},{"key":"370_CR45","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102419884943","volume":"40","author":"E Rubio-Beltran","year":"2020","unstructured":"Rubio-Beltran E, Chan KY, Danser AJ, et al. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia. 2020;40:357\u201366.","journal-title":"Cephalalgia"},{"key":"370_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1468-2982.2004.00830.x","volume":"25","author":"KA Petersen","year":"2005","unstructured":"Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005;25:139\u201347.","journal-title":"Cephalalgia"},{"key":"370_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/j.1365-2125.2010.03869.x","volume":"71","author":"BJ Van der Schueren","year":"2011","unstructured":"Van der Schueren BJ, Blanchard R, Murphy MG, et al. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2011;71:708\u201317.","journal-title":"Br J Clin Pharmacol"},{"key":"370_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-021-01644-5","volume":"82","author":"ED Deeks","year":"2022","unstructured":"Deeks ED. Atogepant: first approval. Drugs. 2022;82:65\u201370.","journal-title":"Drugs"},{"key":"370_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-022-01391-2","volume":"23","author":"X Tao","year":"2022","unstructured":"Tao X, Yan Z, Meng J, et al. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. J Headache Pain. 2022;23:19.","journal-title":"J Headache Pain"},{"key":"370_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40261-022-01130-0","volume":"42","author":"A Singh","year":"2022","unstructured":"Singh A, Balasundaram MK. Atogepant for migraine prevention: a systematic review of efficacy and safety. Clin Drug Investig. 2022;42:301\u20138.","journal-title":"Clin Drug Investig"},{"key":"370_CR51","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14656566.2022.2057221","volume":"23","author":"C Rustichelli","year":"2022","unstructured":"Rustichelli C, Avallone R, Ferrari A. Atogepant: an emerging treatment for migraine. Expert Opin Pharmacother. 2022;23:653\u201362.","journal-title":"Expert Opin Pharmacother"},{"key":"370_CR52","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/TCRM.S348724","volume":"18","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H. Role of atogepant in the treatment of episodic migraines: clinical perspectives and considerations. Ther Clin Risk Manag. 2022;18:447\u201356.","journal-title":"Ther Clin Risk Manag"},{"key":"370_CR53","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1474-4422(20)30282-9","volume":"19","author":"L Al-Hassany","year":"2020","unstructured":"Al-Hassany L, Van Den Brink AM. Targeting CGRP in migraine: a matter of choice and dose. Lancet Neurol. 2020;19:712\u20133.","journal-title":"Lancet Neurol"},{"key":"370_CR54","doi-asserted-by":"publisher","unstructured":"Ashina M, Tepper SJ, Reuter U, et al. Atogepant 60 mg once-daily shows efficacy for the preventive treatment of migraine: results from a 52-week open-label extension trial [abstract no. P-133]. Headache. 2021;61(Suppl 1). https:\/\/doi.org\/10.1111\/head.14130.","DOI":"10.1111\/head.14130"},{"issue":"Suppl 1","key":"370_CR55","first-page":"119","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Halker Singh RB, Mechtler LL, et al. Daily dosing of atogepant for preventive treatment of migraine improved patient reported outcomes measures of migraine-specific quality of life, activity impairment in migraine-diary, and headache-impact test in a 52-week trial [abstract no. P-203]. Headache. 2021;61(Suppl 1):119\u201320.","journal-title":"Headache"},{"key":"370_CR56","doi-asserted-by":"crossref","unstructured":"Ashina M, Tepper S, Reuter U, et al. Long-term safety and tolerability of atogepant 60 mg following once daily dosing over 1 year for the preventive treatment of migraine [abstract]. Neurology. 2021;96(15 Suppl 1). https:\/\/n.neurology.org\/content\/96\/15_Supplement\/2664.full. Accessed Dec 2021.","DOI":"10.1212\/WNL.96.15_supplement.2664"},{"key":"370_CR57","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1358\/dof.2020.45.5.3123467","volume":"45","author":"P Martelletti","year":"2020","unstructured":"Martelletti P, Cipolla F, Capi M, Curto M, Lionetto L. Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, preventive treatment of migraine. Drugs Future. 2020;45:285.","journal-title":"Drugs Future"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00370-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T23:59:44Z","timestamp":1727395184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00370-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00370-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}